Fairmount Funds Management LLC - 22 Jun 2023 Form 3 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Director, 10%+ Owner
Signature
/s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Issuer symbol
SYRE
Transactions as of
22 Jun 2023
Net transactions value
$0
Form type
3
Filing time
30 Jun 2023, 17:32:45 UTC
Previous filing
13 Jun 2023
Next filing
17 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGLE Common Stock 276,082 22 Jun 2023 By Fairmount Healthcare Fund LP( F1
holding AGLE Common Stock 9,184,458 22 Jun 2023 By Fairmount Healthcare Fund II LP F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGLE Stock Option (Right to Buy) 22 Jun 2023 Common Stock 1,950,000 $0.3000 By Peter Harwin F2, F3, F4
holding AGLE Stock Option (Right to Buy) 22 Jun 2023 Common Stock 1,950,000 $0.3000 By Tomas Kiselak F2, F3, F4
holding AGLE Series A Preferred Stock 22 Jun 2023 Common Stock 12,675,000 By Fairmount Healthcare Fund LP F1, F5
holding AGLE Series A Preferred Stock 22 Jun 2023 Common Stock 424,362,000 By Fairmount Healthcare Fund II LP F1, F5
holding AGLE Series A Preferred Stock 22 Jun 2023 Common Stock 85,887,000 By Fairmount Healthcare Co-Invest LP F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund LP, Fairmount Healthcare Fund II LP and Fairmount Healthcare Co-Invest LP. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F2 This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F3 The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
F4 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
F5 Following stockholder approval of the conversion of Series A Preferred Stock into shares of Common Stock, each share of Series A Preferred Stock will automatically convert into 1,000 shares of Common Stock, subject to certain limitations.

Remarks:

The Reporting Persons may each be deemed a director by deputization of Issuer by virtue of the fact that each of Peter Harwin and Tomas Kiselak serve on the board of directors of Issuer and are also each a Managing Member of Fairmount Funds Management LLC.